Leading Infectious Disease Biomaterial Manufacturer

Copan FLOQSwab® and Liquid Control Products
- Clinical Diagnostics,
- Proficiency Programs,
- Training, Verification and Development
Antigens for Diagnostic Test Manufacturers
Viral Transport Medium – DxTM™

Microbix Reports Results for Q1 2026

Microbix reports results for its first quarter of fiscal 2026 ended December 31, 2025 (“Q1”). Results for Q1 demonstrated the Company’s efforts to rebuild revenues back above its breakeven point following two client setbacks in mid-2025, with revenue growth of 13% compared to Q4 fiscal 2025. Q1 revenues and net loss were as-budgeted for fiscal 2026.

Microbix Welcomes The College of American Pathologists as a Client

Microbix is pleased to welcome the College of America Pathologists (“CAP”) as a customer for Microbix quality assessment products (“QAPs™”) for use in CAP clinical laboratory proficiency-testing (“PT”) programs, also commonly known as External Quality Assessments (“EQA”).

Microbix Schedules Release of Results for Q1 Fiscal 2026

Microbix announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its first quarter of
fiscal 2026 ended December 31, 2025 (“Q1 2026”) prior to the start of trading on February 12, 2026.

QAPS

Why choose Microbix Quality Assessment Products (QAPs)? Find out more.

infectious-diseas-antigens-3_55600834-e67d-4aa2-ad6b-59096ce3b3c8

INFECTIOUS DISEASE ANTIGENS

Microbix produces one of the world’s broadest range of infectious disease antigens.

PARTNERSHIP OPPORTUNITIES

Microbix has a partnership opportunity. Check it out here.

Our Commitment to Quality

Our quality process ensures our customers receive products that meet and exceed their needs and expectations. Our quality management system takes into consideration regulatory requirements that are applicable to the type of products we manufacture and the industries we serve.